Logistics company Biocair has partnered with TrakCel and integrated their systems with OCELLOS to improve customer service, automation and visibility in the cell and gene therapy supply chain.
OCELLOS by TrakCel is an integrated cell orchestration solution designed to manage and streamline the cell, gene and immunotherapy supply chain. The platform ensures tracking of both chain of identity and chain of custody, both vital parts of the patient journey, to support the scalability of cell and gene therapy development.
Biocair has been delivering excellence in pharmaceutical, biotech and life science logistics for over 35 years. Most recently, the business has continued its investment in cell and gene therapy logistics by introducing a global team of dedicated specialists to deliver 24-hour global support, as well as collaborating with manufacturers on the design, production, supply and validation of temperature-controlled packaging systems.
Cell and gene therapy offers patients complete personalisation of medicine – a revolutionary way to fight disease. These time-sensitive and life-changing medicines need innovative and flexible logistics solutions to ensure a safe, temperature-controlled and efficient delivery.
Integration with TrakCel’s orchestration platform is essential to ensure a chain of custody whereby all stakeholders have complete visibility of orders in transit. Chris Came, VP of Global Alliances & Client Services at TrakCel, said: “We are so pleased to have such an experienced life sciences logistics specialist on board. By using OCELLOS, Biocair will become completely integrated in the cell and gene therapy supply chain and able to offer patients the best possible service.”
Came continued: “OCELLOS accumulates and automates all the ‘moving parts’ in the cell and gene therapy supply chain. The platform allows visibility and control of onboarding, scheduling, management of timeslots and liaison with couriers. The integration will allow Biocair to further scale their cell and gene therapy logistics, whilst still being customer focussed and offering high levels of service.”
The system integration is a two-way relationship. OCELLOS will ‘speak’ to Biocair to ask for updates and distribute them accordingly to those who need them, whilst Biocair will also receive orders directly from the system.
Chris Good, Director of Cell & Gene Therapy Logistics at Biocair, commented: “Biocair has always been customer focused, but this is even more important in the cell and gene sector. We want to give our customers full visibility and integration within the complex cell and gene therapy supply chain, which is why partnering with TrakCel is essential to providing health care professionals and patients peace of mind that their life-changing medicines will reach them in a timely and safe manner.”